Importance: Bioprosthetic mitral valves are implanted with increasing frequency but inevitably degenerate, leading to heart failure. Reoperation is associated with high morbidity and mortality. Transcatheter mitral valve-in-valve (MViV) using balloon-expandable transcatheter valves has emerged as an alternative for high-surgical risk patients. Objective: To assess contemporary outcomes of SAPIEN 3 (Edwards Lifesciences) MViV replacement. Design, Setting, and Participants: In this registry-based prospective cohort study of SAPIEN 3 MViV, patients entered in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry from June 2015 to July 2019 were analyzed. US Centers for Medicare and Medicaid linkage ensured comprehensive collection of death and stroke data. Exposures: Mitral valve-in-valve for degenerated bioprosthetic mitral valves. Main Outcomes and Measures: The primary efficacy end point was 1-year mortality. The primary safety end point was procedural technical success as defined by the Mitral Valve Academic Research Consortium criteria. Secondary end points included 30-day mortality, New York Heart Association-defined heart failure, and mitral valve performance. Results: A total of 1529 patients (mean [SD] age, 73.3 [11.84] years; 904 women [59.1%]) underwent transseptal or transapical MViV implant at 295 hospitals between June 2015 and July 2019. The mean (SD) Society of Thoracic Surgeons predicted risk of mortality was 11.1% (8.7%). Procedural technical success was achieved for 1480 of 1529 patients (96.8%). All-cause mortality was 5.4% at 30 days and 16.7% at 1 year. Transseptal access was associated with lower 1-year all-cause mortality than transapical access (15.8% vs 21.7%; P = .03). Transcatheter MViV led to early, sustained, and clinically meaningful improvements in heart failure (class III/IV New York Heart Association heart failure of 87.1% at baseline vs 9.7% at 1 year). The mean (SD) mitral valve gradient at 1 year was 7 (2.89) mm Hg. Conclusions and Relevance: Transcatheter MViV using the SAPIEN 3 transcatheter heart valve is associated with high technical success, low 30-day and 1-year mortality, significant improvement of heart failure symptoms, and sustained valve performance. Transseptal MViV should be considered an option for most patients with failed surgical bioprosthetic valves and favorable anatomy.
Importance: Bioprosthetic mitral valves are implanted with increasing frequency but inevitably degenerate, leading to heart failure. Reoperation is associated with high morbidity and mortality. Transcatheter mitral valve-in-valve (MViV) using balloon-expandable transcatheter valves has emerged as an alternative for high-surgical risk patients. Objective: To assess contemporary outcomes of SAPIEN 3 (Edwards Lifesciences) MViV replacement. Design, Setting, and Participants: In this registry-based prospective cohort study of SAPIEN 3 MViV, patients entered in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry from June 2015 to July 2019 were analyzed. US Centers for Medicare and Medicaid linkage ensured comprehensive collection of death and stroke data. Exposures: Mitral valve-in-valve for degenerated bioprosthetic mitral valves. Main Outcomes and Measures: The primary efficacy end point was 1-year mortality. The primary safety end point was procedural technical success as defined by the Mitral Valve Academic Research Consortium criteria. Secondary end points included 30-day mortality, New York Heart Association-defined heart failure, and mitral valve performance. Results: A total of 1529 patients (mean [SD] age, 73.3 [11.84] years; 904 women [59.1%]) underwent transseptal or transapical MViV implant at 295 hospitals between June 2015 and July 2019. The mean (SD) Society of Thoracic Surgeons predicted risk of mortality was 11.1% (8.7%). Procedural technical success was achieved for 1480 of 1529 patients (96.8%). All-cause mortality was 5.4% at 30 days and 16.7% at 1 year. Transseptal access was associated with lower 1-year all-cause mortality than transapical access (15.8% vs 21.7%; P = .03). Transcatheter MViV led to early, sustained, and clinically meaningful improvements in heart failure (class III/IV New York Heart Association heart failure of 87.1% at baseline vs 9.7% at 1 year). The mean (SD) mitral valve gradient at 1 year was 7 (2.89) mm Hg. Conclusions and Relevance: Transcatheter MViV using the SAPIEN 3 transcatheter heart valve is associated with high technical success, low 30-day and 1-year mortality, significant improvement of heart failure symptoms, and sustained valve performance. Transseptal MViV should be considered an option for most patients with failed surgical bioprosthetic valves and favorable anatomy.
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Lee A Fleisher; Hani Jneid; Michael J Mack; Christopher J McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson Journal: J Am Coll Cardiol Date: 2017-03-15 Impact factor: 24.094
Authors: Jaffar M Khan; Vasilis C Babaliaros; Adam B Greenbaum; Jason R Foerst; Shahram Yazdani; James M McCabe; Gaetano Paone; Marvin H Eng; Bradley G Leshnower; Patrick T Gleason; Marcus Y Chen; Dee Dee Wang; Xin Tian; Annette M Stine; Toby Rogers; Robert J Lederman Journal: J Am Coll Cardiol Date: 2019-05-28 Impact factor: 24.094
Authors: Sung-Han Yoon; Brian K Whisenant; Sabine Bleiziffer; Victoria Delgado; Niklas Schofer; Lena Eschenbach; Buntaro Fujita; Rahul Sharma; Marco Ancona; Ermela Yzeiraj; Stefano Cannata; Colin Barker; James E Davies; Antonio H Frangieh; Florian Deuschl; Tomaz Podlesnikar; Masahiko Asami; Abhijeet Dhoble; Anthony Chyou; Jean-Bernard Masson; Harindra C Wijeysundera; Daniel J Blackman; Rajiv Rampat; Maurizio Taramasso; Enrique Gutierrez-Ibanes; Tarun Chakravarty; Guiherme F Attizzani; Tsuyoshi Kaneko; S Chiu Wong; Horst Sievert; Fabian Nietlispach; David Hildick-Smith; Luis Nombela-Franco; Lenard Conradi; Christian Hengstenberg; Michael J Reardon; Albert Markus Kasel; Simon Redwood; Antonio Colombo; Saibal Kar; Francesco Maisano; Stephan Windecker; Thomas Pilgrim; Stephan M Ensminger; Bernard D Prendergast; Joachim Schofer; Ulrich Schaefer; Jeroen J Bax; Azeem Latib; Raj R Makkar Journal: J Am Coll Cardiol Date: 2017-08-29 Impact factor: 24.094
Authors: Lori A Blauwet; Joseph F Malouf; Heidi M Connolly; David O Hodge; Katie N Evans; Regina M Herges; Thoralf M Sundt; Fletcher A Miller Journal: J Am Soc Echocardiogr Date: 2010-06 Impact factor: 5.251
Authors: Michael W Cullen; Allison K Cabalka; Oluseun O Alli; Sorin V Pislaru; Paul Sorajja; Vuyisile T Nkomo; Joseph F Malouf; Frank Cetta; Donald J Hagler; Charanjit S Rihal Journal: JACC Cardiovasc Interv Date: 2013-05-15 Impact factor: 11.195
Authors: Anson Cheung; John G Webb; Marco Barbanti; Melanie Freeman; Ronald K Binder; Christopher Thompson; David A Wood; Jian Ye Journal: J Am Coll Cardiol Date: 2013-02-28 Impact factor: 24.094
Authors: Mackram F Eleid; Brian K Whisenant; Allison K Cabalka; Mathew R Williams; Mohammed Nejjari; David Attias; Neil Fam; Nicholas Amoroso; Thomas A Foley; Peter M Pollak; Oluseun O Alli; Sorin V Pislaru; Sameh M Said; Joseph A Dearani; Charanjit S Rihal Journal: JACC Cardiovasc Interv Date: 2017-10-09 Impact factor: 11.195
Authors: Laura Besola; Anson Cheung; Jian Ye; Myriam Akodad; Andrew Chatfield; Gnalini Sathananthan; Robert Moss; John Webb Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Alina Zubarevich; Marcin Szczechowicz; Konstantin Zhigalov; Philipp Marx; Alexander Lind; Rolf Alexander Jánosi; Tienush Rassaf; Sharaf-Eldin Shehada; Rizwan Malik; Markus Kamler; Matthias Thielmann; Bastian Schmack; Arjang Ruhparwar; Alexander Weymann; Daniel Wendt Journal: Ann Cardiothorac Surg Date: 2021-09
Authors: Matti Adam; Elmar Kuhn; Hendrik Wienemann; Victor Mauri; Laurin Ochs; Maria Isabel Körber; Kaveh Eghbalzadeh; Christos Iliadis; Marcel Halbach; Thorsten Wahlers; Stephan Baldus Journal: Clin Res Cardiol Date: 2022-09-15 Impact factor: 6.138